These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 1865827)
1. Bromocriptine inhibits the seasonally occurring obesity, hyperinsulinemia, insulin resistance, and impaired glucose tolerance in the Syrian hamster, Mesocricetus auratus. Cincotta AH; Schiller BC; Meier AH Metabolism; 1991 Jun; 40(6):639-44. PubMed ID: 1865827 [TBL] [Abstract][Full Text] [Related]
2. Bromocriptine inhibits in vivo free fatty acid oxidation and hepatic glucose output in seasonally obese hamsters (Mesocricetus auratus). Cincotta AH; Meier AH Metabolism; 1995 Oct; 44(10):1349-55. PubMed ID: 7476296 [TBL] [Abstract][Full Text] [Related]
3. Association of the antidiabetic effects of bromocriptine with a shift in the daily rhythm of monoamine metabolism within the suprachiasmatic nuclei of the Syrian hamster. Luo S; Luo J; Cincotta AH Chronobiol Int; 2000 Mar; 17(2):155-72. PubMed ID: 10757461 [TBL] [Abstract][Full Text] [Related]
4. Bromocriptine redirects metabolism and prevents seasonal onset of obese hyperinsulinemic state in Syrian hamsters. Cincotta AH; MacEachern TA; Meier AH Am J Physiol; 1993 Feb; 264(2 Pt 1):E285-93. PubMed ID: 8447396 [TBL] [Abstract][Full Text] [Related]
5. Intracerebroventricular administration of bromocriptine ameliorates the insulin-resistant/glucose-intolerant state in hamsters. Luo S; Liang Y; Cincotta AH Neuroendocrinology; 1999 Mar; 69(3):160-6. PubMed ID: 10087448 [TBL] [Abstract][Full Text] [Related]
6. Bromocriptine reduces obesity, glucose intolerance and extracellular monoamine metabolite levels in the ventromedial hypothalamus of Syrian hamsters. Luo S; Meier AH; Cincotta AH Neuroendocrinology; 1998 Jul; 68(1):1-10. PubMed ID: 9695933 [TBL] [Abstract][Full Text] [Related]
7. Reductions of body fat stores and total plasma cholesterol and triglyceride concentrations in several species by bromocriptine treatment. Cincotta AH; Meier AH Life Sci; 1989; 45(23):2247-54. PubMed ID: 2601578 [TBL] [Abstract][Full Text] [Related]
8. Properly timed injections of cortisol and prolactin produce long-term reductions in obesity, hyperinsulinaemia and insulin resistance in the Syrian hamster (Mesocricetus auratus). Cincotta AH; Wilson JM; deSouza CJ; Meier AH J Endocrinol; 1989 Mar; 120(3):385-91. PubMed ID: 2647890 [TBL] [Abstract][Full Text] [Related]
9. Hepatic vagotomy abolishes the circadian rhythm of lipogenic responsiveness to insulin and reduces fat stores in hamsters. Martin DD; Cincotta AH; Meier AH Neuroendocrinology; 1990 Jul; 52(1):9-14. PubMed ID: 2118610 [TBL] [Abstract][Full Text] [Related]
10. Circadian and seasonal variations of plasma insulin and cortisol concentrations in the Syrian hamster, Mesocricetus auratus. de Souza CJ; Meier AH Chronobiol Int; 1987; 4(2):141-51. PubMed ID: 3334220 [TBL] [Abstract][Full Text] [Related]
11. Circadian rhythms of lipogenic and hypoglycaemic responses to insulin in the golden hamster (Mesocricetus auratus). Cincotta AH; Meier AH J Endocrinol; 1984 Nov; 103(2):141-6. PubMed ID: 6387026 [TBL] [Abstract][Full Text] [Related]
12. Lack of evidence for bromocriptine effect on glucose tolerance, insulin resistance, and body fat stores in obese type 2 diabetic patients. Wasada T; Kawahara R; Iwamoto Y Diabetes Care; 2000 Jul; 23(7):1039-40. PubMed ID: 10895875 [No Abstract] [Full Text] [Related]
13. Central obesity in rhesus monkeys: association with hyperinsulinemia, insulin resistance and hypertriglyceridemia? Bodkin NL; Hannah JS; Ortmeyer HK; Hansen BC Int J Obes Relat Metab Disord; 1993 Jan; 17(1):53-61. PubMed ID: 8383642 [TBL] [Abstract][Full Text] [Related]
14. Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects. Cincotta AH; Meier AH Diabetes Care; 1996 Jun; 19(6):667-70. PubMed ID: 8725871 [TBL] [Abstract][Full Text] [Related]
15. Bromocriptine improves glucose tolerance independent of circadian timing, prolactin, or the melanocortin-4 receptor. Framnes-DeBoer SN; Bakke E; Yalamanchili S; Peterson H; Sandoval DA; Seeley RJ; Arble DM Am J Physiol Endocrinol Metab; 2020 Jan; 318(1):E62-E71. PubMed ID: 31794265 [TBL] [Abstract][Full Text] [Related]
16. Reduction of body fat stores by inhibition of prolactin secretion. Cincotta AH; Meier AH Experientia; 1987 Apr; 43(4):416-7. PubMed ID: 3569491 [TBL] [Abstract][Full Text] [Related]
17. Effect of bromocriptine on insulin, growth hormone and prolactin responses to arginine in obesity. Maccario M; Grottoli S; Procopio M; Oleandri SE; Barberis A; Ciccarelli E; Camanni F; Ghigo E J Endocrinol Invest; 1996 Apr; 19(4):219-23. PubMed ID: 8862501 [TBL] [Abstract][Full Text] [Related]
18. Chronic ventromedial hypothalamic infusion of norepinephrine and serotonin promotes insulin resistance and glucose intolerance. Luo S; Luo J; Cincotta AH Neuroendocrinology; 1999 Dec; 70(6):460-5. PubMed ID: 10657739 [TBL] [Abstract][Full Text] [Related]
19. The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation. Lo JC; Mulligan K; Noor MA; Schwarz JM; Halvorsen RA; Grunfeld C; Schambelan M J Clin Endocrinol Metab; 2001 Aug; 86(8):3480-7. PubMed ID: 11502767 [TBL] [Abstract][Full Text] [Related]
20. What are the physical characteristics associated with a normal metabolic profile despite a high level of obesity in postmenopausal women? Brochu M; Tchernof A; Dionne IJ; Sites CK; Eltabbakh GH; Sims EA; Poehlman ET J Clin Endocrinol Metab; 2001 Mar; 86(3):1020-5. PubMed ID: 11238480 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]